Skip to main content
Premium Trial:

Request an Annual Quote

Sysmex Wins Chinese Approval for Breast Cancer IVD Reagent

NEW YORK — Japanese diagnostics firm Sysmex said on Wednesday that it has received Class III approval from China’s National Medical Products Administration for its Lynoamp BC in vitro diagnostic reagent.

According to Sysmex, the reagent is used for the detection of cytokeratin 19 mRNA in sentinel lymph nodes removed during breast cancer surgery in order to diagnose lymph node metastasis. It is designed to run on the company's RD-100 gene amplification detector system using a proprietary one-step nucleic acid amplification method. Results whether lymph node metastasis has occurred can be achieved within about 30 minutes using Sysmex's technology, the company said.

Sysmex said that it is currently creating a framework for introducing Lynoamp BC-based breast cancer lymph node metastasis testing into the Chinese market.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.